Under the deal, the companies will provide US customers with the Liaison XL Hepatitis A, B, C and HIV products.
Both firms intend to submit the products to the US Food and Drug Administration (FDA) for approval and commercialization in the country.
Once the products are approved, the firms will provide full line of Hepatitis and HIV products, which can run on the Liaison XL LAS connected to Beckman Coulter’s Power Express and Power Processor automated processing systems.
DiaSorin said that it estimates that the total available US market for these products, excluding blood bank testing, exceeds $500m.
DiaSorin is currently providing Liaison XL Hepatitis A, B, C and HIV products to the customers outside the US territory.
Beckman Coulter Diagnostics president Arnd Kaldowski said: “Beckman Coulter and DiaSorin have been working successfully together in China since late last year, helping our customers improve their operations in this key testing area.
“This new agreement is a natural extension of that partnership. Beckman Coulter is very pleased to be working so close with DiaSorin to bring to our customers solutions for their laboratories.”
DiaSorin Group CEO Carlo Rosa said: “After the successful agreement we already signed in China, I’m very proud that Beckman Coulter choose to extend the partnership with us to the U.S. market.”
